Ideaya Biosciences
IDYA36.4002.28% ( +0.810 )
Ideaya Biosciences (IDYA)
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in...
- Open
- 35.500
- High
- 36.480
- Low
- 35.200
- Prev. Close
- 35.590
- Volume
- 740.72K
- Turnover
- 26.65M
- Avg Price
- 35.980
- Bid/Ask Ratio
- --
- Amplitude
- 3.60%
- 52wk High
- 40.580
- Volume Ratio
- 0.90
- Turnover Ratio
- 0.79%
Ideaya Biosciences Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$53.5447.08%
Forecast & RatingStrong buy
15analysts
- Strong buy73.33%
- Buy20.00%
- Hold6.67%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 1 day ago, 04:53 AM
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Redmile Group LLC
- Tip Ranks · Jul 27 at 06:55 AM
IDEAYA Biosciences: Buy Rating Reiterated as Precision Oncology Pipeline Advances and $62 Price Target Maintained
- StockTitan · Jul 26 at 09:00 PM
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers | IDYA Stock News
- PUBT · Jul 17 at 08:00 AM
IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanoma
- StockTitan · Jul 17 at 12:00 AM
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs | IDYA Stock News
- PUBT · Jul 9 at 03:57 PM
IDEAYA Biosciences Chief Accounting Officer Andres Ruiz Briseno sells 9,550 shares for $382,131.94
